Stockscreener 앱 받기
14.66
0.68%
-0.10
시간 외 거래:
14.66
전일 마감가:
$14.76
열려 있는:
$14.7
하루 거래량:
363.06K
Relative Volume:
0.80
시가총액:
$1.01B
수익:
$62.71M
순이익/손실:
$-112.51M
주가수익비율:
5.2357
EPS:
2.8
순현금흐름:
$-96.01M
1주 성능:
+7.01%
1개월 성능:
+16.63%
6개월 성능:
+59.35%
1년 성능:
+97.31%
1일 변동 폭
$14.37
$14.86
1주일 범위
$12.39
$15.00
52주 변동 폭
$6.83
$15.00
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - StockTitan
Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada
Zymeworks (NYSE:ZYME) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World
Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St
Wells Fargo Downgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World
Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Q4 2024 Earnings Preview - MSN
Zymeworks to Spotlight Innovations at Investor Conferences - MSN
Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap DownShould You Sell? - MarketBeat
Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Zymeworks Reports Q3 Results and Strategic Advances - TipRanks
Zymeworks Advances Biotherapeutic Pipeline in 2024 - TipRanks
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zymeworks Q3 2024 Earnings Preview - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Lo - GuruFocus.com
Zymeworks (NYSE:ZYME) PT Raised to $28.00 at Stifel Nicolaus - Defense World
Assenagon Asset Management S.A. Takes Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks Announces Participation in Upcoming Investor Conferences - The Korea Bizwire
Zymeworks (NYSE:ZYME) Price Target Raised to $28.00 at Stifel Nicolaus - MarketBeat
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewswire
Zymeworks (ZYME) Set to Announce Earnings on Thursday - Defense World
Zymeworks retains Neutral stock rating from Wainwright on clinical trials - Investing.com
Zymeworks retains Neutral stock rating from Wainwright on clinical trials By Investing.com - Investing.com South Africa
What Analysts Are Saying About Zymeworks Stock - Benzinga
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer - Clinical Trials Arena
SG Americas Securities LLC Increases Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (NYSE:ZYME) Hits New 52-Week HighShould You Buy? - MarketBeat
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - StockTitan
Zymeworks Inc. announces board changes By Investing.com - Investing.com Nigeria
Zymeworks Inc. announces board changes - Investing.com India
Zymeworks Announces Board Changes with New Appointments - TipRanks
Zymeworks Inc. Announces Board and Committee Changes - Marketscreener.com
Zymeworks Announces Participation in Upcoming Investor Conference, Business Wires News - AsiaOne
Zymeworks (NASDAQ:ZYME) grows 6.5% this week, taking one-year gains to 89% - Simply Wall St
Zymeworks stock soars to 52-week high, hits $13.3 By Investing.com - Investing.com South Africa
Zymeworks (NYSE:ZYME) Reaches New 12-Month HighTime to Buy? - MarketBeat
Zymeworks stock soars to 52-week high, hits $13.3 - Investing.com India
AQR Capital Management LLC Cuts Stake in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):